He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.

Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction. Biographies Reenie McCarthy is the Chief Executive Officer, President and a member of t

CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS. Coverage brought to you by

He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026. Coverage brought to you by

CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans. Coverage brought to you by

He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka. Coverage brought to you by

He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond. Coverage brought to you by

He comments on IPOs, fundraising, M&A, and China. Coverage brought to you by

CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD. Coverage brought to you by

CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer. Coverage brought to you by

CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs. Coverage brought to you by

Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis. Coverage brought to you by

He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne. Coverage brought to you by

CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile. Coverage brought to you by

Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.

Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders. Chapters Early life end education – 3:31 Helping his brother run a genomics company - 10:28 Creating a seed fund – 16:50 North Carolina's strengths – 25:51 Bob Ingram – 29:56 Investing local and beyond – 4

CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.

CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.